ARCHIVES

Pfizer Begins Phase III Trial Of Sunitinib In NSCLC

This article is from The Cancer Letter archive.

Vol. 30 No. 9 | September 28, 2007

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Task Force Hears Update on Research, Abstract Excerpter

September 19, 1980

Benefit Seen In Novel Drug That Treats Gleevec Resistance

April 29, 2005

DCPC Advisors Approve Five New RFA concepts, Set Aside $33.6 Million

June 4, 1993

After Furlough, Blizzard, NCI Struggles to Clear Backlog and Resume Business

January 19, 1996

As patients worry about COX-2 inhibitors, scientists and FDA review toxicity data.

October 22, 2004

Cancer center directors to develop blueprint for progress that’s “honest,” M.D. Anderson’s John Mendelsohn says.

November 23, 2005